Back to today’s briefing

Story perspectives

Insilico Medicine's AI Revolutionizes Drug Development and Trials

1/10/2025

27 3

Summary

Story summary

Insilico Medicine, co-founded by Dr. Alex Zhavoronkov, is revolutionizing drug development with AI, targeting diseases like idiopathic pulmonary fibrosis (IPF). With six molecules currently in clinical trials, the company is slashing drug discovery time, paving the way for faster, more effective treatments in a world hungry for innovation.

1 of 1

Story summary

Insilico Medicine, co-founded by Dr. Alex Zhavoronkov, is revolutionizing drug development with AI, targeting diseases like idiopathic pulmonary fibrosis (IPF). With six molecules currently in clinical trials, the company is slashing drug discovery time, paving the way for faster, more effective treatments in a world hungry for innovation.